<DOC>
	<DOCNO>NCT00493987</DOCNO>
	<brief_summary>In normal men , male hormone testosterone affect number thing body include muscle function sexual function . An enzyme body call 5-alpha reductase convert testosterone another form call dihydrotestosterone ( DHT ) slightly different effect . The purpose study find different amount two different form testosterone affect muscle function sexual function healthy young men like . This do give men participate study different combination hormone-related medication 20 week make measurement , medication look change lean body tissue , muscle size , muscle strength leg power , well sexual function sexual activity participant .</brief_summary>
	<brief_title>The Role 5-alpha Reductase Mediating Testosterone Actions</brief_title>
	<detailed_description>Testosterone , predominant circulate androgen men , also serve prohormone convert body two active metabolite , estradiol 17 β 5-α DHT ( DHT ) . Testosterone serf active hormone target tissue ; however , androgen effect target organ require conversion estradiol DHT . The role 5-α reduction testosterone mediate effect muscle sexual function remain unclear . Therefore , primary objective project determine whether 5-α reduction testosterone DHT obligatory mediate effect fat-free mass , muscle size , muscle strength , leg power men . The secondary objective determine whether 5-α reduction testosterone necessary maintenance androgen effect sexual function ( sexual desire , overall sexual activity , nocturnal penile tumescence ( NPT ) , response visual erotic stimulus , penile rigidity ) men . In order test hypotheses role 5-α reduction , compare testosterone dose response curve outcome measure absence presence novel , potent 5-α reductase inhibitor ( dutasteride ) inhibit type 1 type 2 steroid 5-α -reductase isoenzymes . Healthy young men , 21-40 year age , treat long act GnRH agonist suppress endogenous testosterone production , concomitantly , randomly assign one 8 group : group 1 , testosterone enanthate ( TE ) 50-mg weekly , plus placebo tablet daily ; group 2 , TE 125-mg weekly plus placebo daily ; group 3 , TE 300-mg weekly plus placebo daily ; group 4 , TE 600 mg TE weekly plus placebo ; group 5 , 50-mg weekly , plus dutasteride 2.5-mg daily ; group 6 , TE 125-mg weekly , plus dutasteride daily ; group 7 , TE 300 mg weekly , plus dutasteride daily ; group 8 , 600-mg TE plus dutasteride daily . Energy protein intake , exercise stimulus standardize . The following outcome measure baseline 20 week : body composition DEXA scan , deuterium oxide sodium bromide dilution ; thigh muscle volume MRI scan ; muscle performance measurement 1-repetition maximum strength leg power ; sexual function International Index Erectile Function , Sexual Desire Inventory , daily log sexual activity ; penile erection rigidity EEG-coupled , NPT recode response visual erotic stimulus ; total free testosterone , DHT , estradiol , SHBG , LH level . For safety , follow hemoglobin/hematocrit , sleep apnea score , AST ALT , PSA , plasma lipid , apolipoproteins , lipoprotein particle , prostate examination . A multi-disciplinary team investigator , use previously validate `` Leydig Cell Clamp '' model , use potent inhibitor subtypes 5-alpha reductase enzyme , attention potential confounding variable energy intake exercise stimulus , power effect size help elucidate role 5-alpha reduction mediate androgen action . This study enhance understand biologic role steroid 5-alpha-reductase system , immediate clinical relevance establish whether selective androgen receptor modulators undergo 5-alpha reduction would useful anabolic agent .</detailed_description>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Healthy male 18 50 year age . Ambulatory , physically active , competitive sport . Eugonadal : Normal Serum Testosterone ( 3001100 nmol/L ) . Normal LH Normal FSH Able willing comply trial protocol . Known primary secondary hypogonadism ? ( e.g . pituitary disease , HIV infection , Klinefelter 's Syndrome ) BMI &gt; 35 Disability precludes participation exercise test Alcohol illicit drug use precede 6 month would interfere participation compliance protocol Known disorder would exacerbate androgen treatment e.g . benign prostate hyperplasia , prostate Ca , erythrocytosis , sleep apnea ) Any abnormality follow laboratory test PSA &gt; 4 ng/ml AST , ALT Alkaline Phosphatase &gt; 3x ULN ? Creatinine level &gt; 2 mg/dL Hematocrit &gt; 51 % Osteoporosis DEXA BMD TScore &lt; 2.5 Use medication affect muscle bone metabolism within previous 3 month ? ( e.g . glucocorticoid , growth hormone , androgenic steroid , oral androgen precursor i.e . androstenedione DHEA ) Use medication affect androgen metabolism , action clearance within previous 3 month ? ( e.g . dilantin , phenobarbital , aldactone , flutamide , finasteride Ketoconazole ) Use ketoconazole potent CYP3A4 inhibitor may affect clearance dutasteride Use investigational medication part research study last 3 month ?</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Testosterone</keyword>
	<keyword>Androgens</keyword>
	<keyword>Dihydrotestosterone</keyword>
	<keyword>5-alpha reductase</keyword>
	<keyword>Body Composition</keyword>
	<keyword>Muscle</keyword>
	<keyword>Sexual function</keyword>
	<keyword>Men</keyword>
	<keyword>Healthy Men</keyword>
</DOC>